GIAPREZA® (angiotensin II) 2.5mg/ml concentrate for solution for infusion: potentially low fill vials and important information regarding instructions for use

Dear Healthcare professional,

PAION Deutschland GmbH in agreement with the European Medicines Agency and the <National Competent Authority > would like to inform you of the following:

Summary

- **Several hospitals in the United States have identified low fill vials (not filled to the required volume) of GIAPREZA® (angiotensin II) product lot 2457-116, corresponding to product batches 23GPZ001, 23GPZ002, 23GPZ003, 23GPZ004, 23GPZ005, 23GPZ006 and 23GPZ008 in Europe, one or more of which have been supplied to your health institution.**
- **It has been reported that when the contents of a vial are withdrawn into a syringe the volume is less than the 1 mL volume defined in the product information.**
- **If Giapreza is withdrawn from a low fill vial, there will not be enough of the drug to achieve a concentration of 5,000ng/ml or 10,000ng/ml when it is diluted with the amount of sodium chloride (0.9%) specified in the product information. This may result in underdosing and potentially a slower onset of effect.**
- **Patient safety is not impacted.**
- **Should you identify a vial with less than 1 ml volume, discard the vial and use another new vial.**
- **Any impacted vials found to have less than 1 mL volume will be replaced upon request (see Annex 1 below for instructions).**
- **So far, there have been no reports of low fill vials in the EU.**

Background – Instructions for Use

GIAPREZA® (2.5 mg/ml concentrate for solution for infusion with 2.5mg angiotensin II/vial) is a vasoconstrictor used for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. The recommended starting dosage of GIAPREZA is 20 nanograms (ng)/kg per minute via continuous intravenous infusion.

GIAPREZA must be diluted in sodium chloride 9 mg/ml (0.9%) solution for injection prior to use. One millilitre of GIAPREZA must be diluted in sodium chloride 9 mg/ml (0.9%) solution for injection to achieve a final concentration of 5,000 ng/ml (using 500 ml infusion bag size) or 10,000 ng/ml (using 250 ml infusion bag size). Please refer to the product information 4.2 Posology and method of administration (Table 1 Preparation of diluted solution).

When initiating GIAPREZA, it is important to closely monitor blood pressure response and adjust dose accordingly.

PAION received information from the GIAPREZA supplier that there were several reports of low fill vials notified by some hospitals in the United States. All of these reports relate to product lot 2457-116 which was released in Europe as product batches 23GPZ001, 23GPZ002, 23GPZ003, 23GPZ004, 23GPZ005, 23GPZ006 and 23GPZ008. One of these batches has been supplied to your health institution. It has been reported that when the contents of a vial are withdrawn into a syringe the volume is less than the 1 mL volume defined in the product information.

PAION wants to emphasize important information:

- This notification only applies to GIAPREZA® (Angiotensin II) 2.5mg/vial from the product batches 23GPZ001, 23GPZ002, 23GPZ003, 23GPZ004, 23GPZ005, 23GPZ006 and 23GPZ008.
- Please carefully monitor the volume withdrawn from each vial.
- Should you identify a vial with less than 1 ml volume, discard the vial and use another new one.
- It has been determined that patient safety is not impacted .

Call for reporting

Healthcare professionals should report any suspected adverse reactions associated with the use of GIAPREZA in accordance with the national spontaneous reporting system *<include the details (e.g. name, postal address, fax number, web address) on how to access the national spontaneous reporting system>.*

GIAPREZA is subject to additional monitoring as it contains a new active substance (angiotensin II).

Company contact point

Medical Information at PAION Deutschland GmbH

Heussstraße 25
52078 Aachen
Germany
medinfo@paion.com

Annexes

ANNEX 1: Replacement Directions

PAION will provide a replacement for any impacted GIAPREZA vials. For product replacement, please contact

Supply Chain at Paion Deutschland GmbH
Heussstraße 25
52078 Aachen
Germany

Email: SC@paion.com

Phone: +49 241 4453 0

Communication Plan for Direct Healthcare Professional Communication

DHPC COMMUNICATION PLAN	
Medicinal product(s)/active substance(s)	GIAPREZA® (angiotensin II) 2.5 mg/ml concentrate for solution for infusion
Marketing authorisation holder(s)	PAION Deutschland GmbH
Safety concern and purpose of the communication	GIAPREZA® (angiotensin II) 2.5 mg/ml concentrate for solution for infusion: potentially low fill vials and important information regarding instructions for use
DHPC recipients	Healthcare providers who can administer Giapreza. The target group will be further defined at national level, in agreement with the respective national competent authority
Member States where the DHPC will be distributed	All EU/EEA Member States where the affected Giapreza batches 23GPZ001, 23GPZ002, 23GPZ003, 23GPZ004, 23GPZ005, 23GPZ006 and 23GPZ008 were distributed.

Timetable	Date
DHPC and communication plan (in English) agreed by CHMP/CMDh	25 April 2024
Submission of translated DHPCs to the national competent authorities for review	Date of CHMP opinion +14 calendar days
Agreement of translations by national competent authorities	Date of CHMP opinion +21 calendar days (depending on NCA)
Dissemination of DHPC	Date of CHMP opinion +28 calendar days